The interactions that matter most are with insulin and sulfonylureas (hypoglycemia risk), oral contraceptives (reduced absorption), and any oral medication with a narrow therapeutic index, because delayed gastric emptying changes absorption timing.
On this page
Insulin and sulfonylureas
Tirzepatide's glucose-lowering effect stacks with these agents and can cause hypoglycemia. Doses of background therapy frequently need reduction when tirzepatide is started or escalated. This requires a prescriber who knows your full medication list — a reason to be skeptical of any platform that never asks.
Oral contraceptives
See the pregnancy guide. Switch to a non-oral method or add a barrier method for four weeks after starting and after each dose increase.
Anything with a narrow therapeutic window
Delayed gastric emptying changes when an oral drug enters the bloodstream. For most medications this is clinically irrelevant. For levothyroxine, warfarin, some antiepileptics and immunosuppressants, tell your prescriber and expect monitoring.
Before surgery or an endoscopy
Professional society guidance has recommended holding weekly GLP-1 agonists before elective procedures requiring sedation because of retained gastric contents and aspiration risk, with specific intervals varying by guideline and being actively revised. Tell your anesthetist and your surgeon that you take tirzepatide, and follow their instruction rather than a general rule.
Common questions
Is tirzepatide better than semaglutide?
For weight loss, yes, on the available randomized evidence. SURMOUNT-5 compared them head-to-head over 72 weeks and found 20.2% mean loss on tirzepatide versus 13.7% on semaglutide. Semaglutide retains a stronger cardiovascular outcomes label from the SELECT trial and is cheaper in compounded form.
What dose of tirzepatide do most people end up on?
Most people settle between 7.5 mg and 12.5 mg. The efficacy gain from 10 mg to 15 mg was only about 1.4 percentage points in SURMOUNT-1, while side effects and often price continue to rise. Many people never need 15 mg.
Why do tirzepatide prices go up as my dose increases?
Because some programs price by dose tier rather than charging one rate. The advertised price usually reflects the 2.5 mg starter dose, which you occupy for about four weeks. Flat-rate programs charge the same amount at every dose. Over twelve months that structural difference typically matters more than any first-month discount.
What happens if I stop taking tirzepatide?
Weight regain is expected. In SURMOUNT-4, participants who switched to placebo after 36 weeks regained 14% of body weight over the following year, while those who continued lost a further 5.5%. Obesity behaves as a chronic condition and treatment is generally open-ended.
People also ask about glp1 drug interactions
What is glp1 drug interactions?
Glp1 drug interactions is covered in full on this page, with the clinical detail drawn from the tirzepatide prescribing information and the published SURMOUNT and SURPASS trial program, and any price figures drawn from our tracked dataset and dated to their last verification.
Does glp1 drug interactions apply to compounded tirzepatide as well as Zepbound?
The molecule is the same, so the clinical content applies to both. What differs is regulatory status, dose metering and price: compounded preparations are not FDA-approved, arrive as a multi-dose vial you measure yourself, and cost a fraction of the brand routes.
How much does glp1 drug interactions cost per month in 2026?
Compounded tirzepatide runs from $133 per month at the entry dose across the 21 compounded programs we track. At a 10 mg maintenance dose the cheapest tracked route is Oak Longevity at $199 per month, or about $2,388 for a first year on the standard escalation. Brand Zepbound through manufacturer self-pay sits well above that and pharmacy retail well above again. Verified 2026-08-05.
Is glp1 drug interactions FDA-approved?
Brand tirzepatide (Zepbound and Mounjaro) is FDA-approved. Compounded tirzepatide is not: FDA does not approve compounded drugs and does not review them for safety, effectiveness or quality before they are marketed. The active molecule is the same; the regulatory review is not.
Primary sources
Clinical, dosing and regulatory statements on this page rest on the documents below. Links go to the publisher, not to a summary of it. Prices are not sourced here — they carry a verification date instead, and the reason is set out in the source ledger.
- ZEPBOUND (tirzepatide) full prescribing information — DailyMed, US National Library of Medicine. Dose ladder, contraindications, warnings, storage.
- FDA’s concerns with unapproved GLP-1 drugs used for weight loss — US Food and Drug Administration. Compounded GLP-1 risks, API import alert, cold-chain complaints.
- FD&C Act provisions that apply to human drug compounding — US Food and Drug Administration. Why a compounded preparation is lawful without being FDA-approved.
- Tirzepatide once weekly for the treatment of obesity (SURMOUNT-1) — N Engl J Med 2022;387:205-216. Registration NCT04184622. The weight-reduction and adverse-event figures used across this site.
- The full source ledger — every primary source, what it supports, the date we read it, and the claims we deliberately do not source.